Abstract |
Lenalidomide is an immunomodulatory drug which is used to treat patients with MDS with deletion 5q chromosomal abnormality. In 2008, WHO introduced a new disease entity called MDS/MPN. No specific treatment for MDS/MPN subtype has yet been identified. We report a patient with MDS/MPN who responded well to lenalidomide therapy.
|
Authors | Anwarul Islam |
Journal | Clinical case reports
(Clin Case Rep)
Vol. 3
Issue 7
Pg. 551-2
(Jul 2015)
ISSN: 2050-0904 [Print] England |
PMID | 26273440
(Publication Type: Case Reports)
|